VanEck Associates
AXSM icon

VanEck Associates’s Axsome Therapeutics AXSM Stock Holding History

VanEck Associates’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.37M Buy
37,673
+2,596
+7% +$448K ﹤0.01% 739
2025
Q4 		$6.41M Buy
35,077
+20,204
+136% +$2.82M 0.01% 711
2025
Q3 		$1.81M Sell
14,873
-1,460
-9% -$164K ﹤0.01% 999
2025
Q2 		$1.71M Sell
16,333
-46,662
-74% -$4.94M ﹤0.01% 971
2025
Q1 		$7.35M Buy
+62,995
New +$7.18M 0.01% 571

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VanEck Associates's AXSM Position: Q1 2026 in Review

VanEck Associates increased its Axsome Therapeutics (AXSM) stake by 7.4% in Q1 2026, buying an estimated $448K and bringing the position to 37,673 shares worth $6.37M. The position accounts for ﹤0.01% of the portfolio, ranked #739.

VanEck Associates first reported a position in AXSM in Q1 2025 and has held it in 5 quarters since. The position peaked at $7.35M in Q1 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • VanEck Associates held 37,673 shares of Axsome Therapeutics worth $6.37M as of Q1 2026.
  • VanEck Associates bought 2,596 Axsome Therapeutics shares in Q1 2026, an estimated $448K.
  • Axsome Therapeutics made up ﹤0.01% of VanEck Associates's portfolio in Q1 2026, its #739 holding.
  • VanEck Associates first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • VanEck Associates's Axsome Therapeutics position peaked at $7.35M in Q1 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.